聚焦伯恩斯坦_强生2026年第一季度:尽管面临Stelara的不利影响仍实现稳健增长,医疗器械业务前景令人鼓舞。There was no evidence of material weather- or flu-related procedure deferrals in JNJ Q1 results, which medtech investors should find encouraging.See the Disclosure Appendix of this report for required disclosures, analyst certifications and other important information. Alternatively, visit our Global Research Disclosure Website.
聚焦伯恩斯坦_强生2026年第一季度:尽管面临Stelara的不利影响仍实现稳健增长,医疗器械业务前景令人鼓舞。There was no evidence of material weather- or flu-related procedure deferrals in JNJ Q1 results, which medtech investors should find encouraging.See the Disclosure Appendix of this report for required disclosures, analyst certifications and other important information. Alternatively, visit our Global Research Disclosure Website.
聚焦伯恩斯坦_强生2026年第一季度:尽管面临Stelara的不利影响仍实现稳健增长,医疗器械业务前景令人鼓舞。There was no evidence of material weather- or flu-related procedure deferrals in JNJ Q1 results, which medtech investors should find encouraging.See the Disclosure Appendix of this report for required disclosures, analyst certifications and other important information. Alternatively, visit our Global Research Disclosure Website.
覆盖 2026 年,全文共 17 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合行业研究员、战略规划等读者参考。
重点分析了医疗器械等议题。